http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018060463-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23e392458c31d58d9bb31ddd8ac23ef1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c5e77c181522ee1fd44df1ae5ac2196 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-501 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 |
| filingDate | 2017-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4434455a356db3cf5aa3efecfb931472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41cd79b86ba560c90fed61839f485da8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e99e09f91c2e5c759c9ff109f962f54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a03994c5c1ca79d4a259d3d5d8c37fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87e35c95f6d376ad0e17915c2a1bcc54 |
| publicationDate | 2018-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2018060463-A3 |
| titleOfInvention | Treatment of prostate cancer |
| abstract | Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethyiamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. |
| priorityDate | 2016-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227061017 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10348973 |
Total number of triples: 23.